HMGB1 and colitis: Hany et al. revealed that dapagliflozin exerts ameliorative effects on experimental colitis by inhibiting the HMGB1/RAGE/NF-κB cascade through activation of the AMPK/mTOR and Nrf2/HO-1 pathways, augmenting colon autophagy and inhibiting apoptosis [60].